NCT04799990View on ClinicalTrials.gov

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

June 23, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

March 10, 2022

Conditions
Psoriasis
Interventions
DRUG

Risankizumab

Subcutaneous Injection

BIOLOGICAL

Comparator 1

Subcutaneous or Intravenous Injection

DRUG

Comparator 2

Oral, Opthalmic, Subcutaneous or Intravenous Injection

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY